Charissa Fay Borja-Tabora

Publications (1)3.77 Total impact

• Article: Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.

  Lucy Chai See Lum, Charissa Fay Borja-Tabora, Robert F Breiman, Timo Vesikari, Benjamin P Sablan, Oh Moh Chay, Taweewong Tantracheewathorn, Heinz-Josef Schmitt, Yu-Lung Lau, Piyaporn Bowonkiratikachorn, [......], Petras Kaltenis, Andre Vertruyen, Hanna Czajka, Jurgis Bojarskas, W Abdullah Brooks, Sheau-Mei Cheng, Ruth Rappaport, Sherryl Baker, William C Gruber, Bruce D Forrest
  [show abstract] [hide abstract]
  ABSTRACT: Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35+/-7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV+Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively).
  Vaccine 12/2009; 28(6):1566-74. · 3.77 Impact Factor